The central government has regulated prices for 71 essential medicines. This includes drugs for breast cancer, allergies, and ...

In the long and often dispiriting quest to cure cancer, the 1998 approval of the drug Herceptin was a tremendously hopeful moment. This drug for breast cancer was the first to use a tumor-specific ...

Only with the adoption of digital imaging and AI-powered analysis will next-generation precision oncology therapies reach ...

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s ...

Jazz Pharmaceuticals (($JAZZ)) announced an update on their ongoing clinical study. The clinical study titled A Phase 3, Randomized, Open-label, ...

The global Biosimilars Market , valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

Treatment using Imcranib 100 is now available at Chulabhorn Hospital, signicantly reducing treatment costs and increasing ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

Emiltatug ledadotin shows promising antitumor activity in various cancers, with manageable safety, highlighting its potential ...

A new paper, published in Acta Oncologica, represents the culmination of a series of outputs stemming from an all island 88 patient clinical trial involving eight different hospitals beginning in 2010 ...

Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change care for patients in the future.

Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...